All In Biotech

Drug Trial Radar · NCT01014741

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Modified Stepwise Ablation Guided by Low Dose Ibutilide in Chronic Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Feb 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Oct 2009

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
Vivek ReddyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbott Medical Devices
First posted
Nov 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Procedures for ablation of persistent or long lasting atrial fibrillation are frequently long and require extensive ablation. Some electrophysiologists administer the drug ibutilide during these procedures to help organize the fibrillatory activity of the left atrium with the hope that this may shorten the length of the procedure and duration of ablation needed. Currently there is no standardized approach of administering the drug ibutilide during these procedures, thus the investigators cannot be certain that administering this drug does in fact facilitate the procedure. The aim of the MAGIC-AF Trial is to see if administering a standard dose of the drug ibutilide at a standard time in the procedure can allow for a reduction in the ablation procedure time. The investigators hypothesize that administering ibutilide during these procedures will result in a reduction in the procedure and ablation time required.

Conditions

  • Persistent Atrial Fibrillation

Interventions

  • IbutilideDrug

    0.25mg IV ibutilide after PV isolation prior to CFE ablation

  • PlaceboDrug

    Placebo after PV isolation prior to CFE ablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With 1 Year Freedom From AF / ATTime frame: one year

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Regional Cardiology Associates

    Sacramento, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University Of Virginia Health System

    Charlottesville, Virginia

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Republic of Korea University Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.